Vanda adopts limited-duration rights plan; rejects Future Pak's $7.25-$7.75/share bid

Vanda Pharmaceuticals Inc.

Board adopted a one-year stockholder rights plan effective April 17, 2024, triggered at 10% beneficial ownership.
Plan adopted in response to unsolicited proposals from Future Pak; latest offered $7.25–$7.75 per share.
Board unanimously rejected proposals as significantly undervaluing the company, citing robust pipeline and $6.75 cash per share.
Rights dividend payable to shareholders of record April 29, 2024; rights expire April 16, 2025.
Plan prevents open-market accumulation without a control premium; no shareholder action required.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vanda Pharmaceuticals Inc. entered into Rights Agreement with Equiniti Trust Company, LLC (effective 2024-04-17).

Action: entry
Counterparty: Equiniti Trust Company, LLC
Effective: 2024-04-17

Exact text from the filing

The complete terms of the Rights are set forth in a Rights Agreement (the “Rights Agreement”), dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-099251

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.